Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Slipek

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Nature Biomedical Engineering|December 13, 2023
Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repairBeau R Webber, Matthew J Johnson, Joseph G Skeate, et al.
Nature Communications|November 21, 2019
Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editorsBeau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, et al.
Nature Communications|April 24, 2021
CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cellsMitchell G Kluesner, Walker S Lahr, Cara-Lin Lonetree, et al.
Oncogene|October 5, 2019
SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasisBranden A Smeester, Nicholas J Slipek, Emily J Pomeroy, et al.
Nature Communications|December 8, 2019
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editorsBeau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, et al.
Journal for Immunotherapy of Cancer|May 9, 2025
Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editingMinjing Wang, Joshua B Krueger, Alexandria K Gilkey, et al.
Bone|April 7, 2020
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcomaBranden A Smeester, Nicholas J Slipek, Emily J Pomeroy, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
A Singular Base Editing Platform for Polyfunctional Multiplex Engineering of Immune CellsJoseph G Skeate, Nicholas J Slipek, Walker S Lahr, et al.
Molecular Cancer Therapeutics|October 1, 2020
Implication of <i>ZNF217</i> in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic OsteosarcomaBranden A Smeester, Garrett M Draper, Nicholas J Slipek, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 17, 2024
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapiesJoseph G Skeate, Emily J Pomeroy, Nicholas J Slipek, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Nature Biomedical Engineering|December 13, 2023
Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repairBeau R Webber, Matthew J Johnson, Joseph G Skeate, et al.
Nature Communications|November 21, 2019
Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editorsBeau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, et al.
Nature Communications|April 24, 2021
CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cellsMitchell G Kluesner, Walker S Lahr, Cara-Lin Lonetree, et al.
Oncogene|October 5, 2019
SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasisBranden A Smeester, Nicholas J Slipek, Emily J Pomeroy, et al.
Nature Communications|December 8, 2019
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editorsBeau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, et al.
Journal for Immunotherapy of Cancer|May 9, 2025
Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editingMinjing Wang, Joshua B Krueger, Alexandria K Gilkey, et al.
Bone|April 7, 2020
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcomaBranden A Smeester, Nicholas J Slipek, Emily J Pomeroy, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
A Singular Base Editing Platform for Polyfunctional Multiplex Engineering of Immune CellsJoseph G Skeate, Nicholas J Slipek, Walker S Lahr, et al.
Molecular Cancer Therapeutics|October 1, 2020
Implication of <i>ZNF217</i> in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic OsteosarcomaBranden A Smeester, Garrett M Draper, Nicholas J Slipek, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 17, 2024
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapiesJoseph G Skeate, Emily J Pomeroy, Nicholas J Slipek, et al.
Pageof 3